Hurtado-López LM, Miracle-López S

Language: Spanish
References: 16
Page: 13-16
PDF size: 139.54 Kb.

ABSTRACT

Background: The objective of this study is to evaluate the elevation of TSH and the quality of life after the administration of recombinant human thyrotropin (rhTSH) for the treatment and follow-up of papillary thyroid cancer without hypothyroidism. Material and methods: Prospective, longitudinal, comparative study. Two groups were compared; G1: patients without hypothyroidism and administration of rhTSH, G2: patients with four weeks hypothyroidism. Studied variables: levels of TSH, quality of life, cold intolerance, dry skin, palpebral edema, foot edema, constipation, sleep disorders, weight gain, diminished physical activity, memory loss and general side effects. The statistical analysis was made by means of chi square and Fisher and Yates exact probability, with level of significance of p = 0.05. Results: G1 (n = 21) and G2 (n = 25). In both groups the TSH rose above of 30 µU/mL and the average of elevation of each group did not have statistical difference (p = 0.098). The evaluation of quality of life had statistical difference (p ‹ 0.001) in favor of G1. All the other variables also had statistically significant difference (p ‹ 0.001) in favor of G1. One G1 patient felt nausea of slight intensity. Conclusion: The administration of recombinant human thyrotropin offers adequate levels of TSH elevation without altering the quality of life.

REFERENCES

1. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001; 86: 1447-1463.

2. Hurtado-López LM, Zaldívar-Ramírez FR. Tiroidectomía o hemitiroidectomía para el tratamiento de cáncer diferenciado de tiroides. Cir Gen. 2005; 27: 9-13.

3. Thyroid Carcinoma Task Force. AACE/AAES medical/surgical guidelines for the clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract. 2001; 7: 202-220.

4. Lippi F, Capezzone M, Angelini F, Taddei D, Molinaro E, Pinchera A et al. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. Eur J Endocrinol. 2001; 144: 5-11.

5. Chow SM, Au KH, Choy TS, Lee SH, Yeung NY, Leung A et al. Health-related quality-of-life study in patients with carcinoma of the thyroid after thyroxine withdrawal for whole body scanning. Laryngoscope. 2006; 116: 2060-2066.

6. Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid. 1997; 7: 613-619.

7. Tagay S, Herpertz S, Langkafel M, Erim Y, Freudenberg L, Schopper N et al. Health-related quality of life, anxiety and depression in thyroid cancer patients under short-term hypothyroidism and TSH-suppressive levothyroxine treatment. Eur J Endocrinol. 2005; 153: 755-763.

8. Huang SH, Wang PW, Huang YE, Chou FF, Liu RT, Tung SC et al. Sequential follow-up of serum thyroglobulin and whole body scan in thyroid cancer patients without initial metastasis. Thyroid. 2006; 16: 1273-1278.

9. Sosa JA, Udelsman R. Total thyroidectomy for differentiated thyroid cancer. J Surg Oncol. 2006; 94: 701-707.

10. Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab. 2005; 90: 5047-5057.

11. Mazzaferri EL, Massoll N. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr Relat Cancer. 2002; 9: 227-247.

12. Mazzaferri EL, Kloos RT. Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions. Thyroid. 2000; 10: 767-778.

13. Robbins RJ, Driedger A, Magner J; US and Canadian Thyrogen Compassionate Use Program Investigator Group. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid. 2006; 16: 1121-1130.

14. Pacini F, Molinaro E, Lippi F, Castagna MG, Agate L, Ceccarelli C. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2001; 86: 5686-5690.

15. David A, Blotta A, Rossi R, Zatelli MC, Bondanelli M, Roti E et al. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma. Thyroid. 2005; 15: 158-164.

16. Berg G. Radioiodine treatment for malignant thyroid disease. Acta Oncol. 2006; 45: 1041-1045.